Proactive Investors - Run By Investors For Investors

Lojuxta 'exceeding expectations' - Amryt Pharma's Joe Wiley

Joe Wiley, chief executive of Amryt Pharma PLC (LON:AMYT) tells Proactive a product that it licensed the rights to is performing better than expected.

Lojuxta treats a rare and life-threatening condition called Homozygous Familial Hypercholesterolemia, which causes abnormally high levels of bad cholesterol.

Revenues from the treatment were €5.75mln for the six months ended June; the company’s total sales for the period were €6.18mln.

 
Meet Metro Mining Ltd and Meteoric Resources NL at our event, Melbourne , 10 April 2019. Register here »
View full AMYT profile View Profile

Amryt Pharma PLC Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use